How blood based biomarkers are reshaping the Alzheimer’s testing pathway

Description

Discover the future of Alzheimer's disease testing in our upcoming webinar, where we’ll explore the transformative role of blood biomarkers. Growing demand for early disease stage diagnosis and regulatory approvals of Alzheimer’s disease blood biomarker tests can drive their accelerated integration into clinical laboratory routine workflows. This insightful webinar is designed to provide attendees with an understanding of clinical and practical considerations, ultimately empowering them to make more informed decisions. Learn from experts about the clinical value and applications of these biomarkers, which could position your laboratory at the forefront of Alzheimer’s disease testing.

Target audience

This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), medical technologists, pathologists, fellows, residents, in-training individuals, and other laboratory professionals overseeing/conducting within this topic.

Learning objectives

At the end of this session, participants will be able to:

• Discuss the increHonorasing importance of blood biomarkers in early diagnosis of Alzheimer’s disease.
• Recognize clinical and practical applications of different biomarkers to shape and support informed decision making.
• Apply the knowledge on how plasma biomarkers integrate in the evolving patient pathway and the clinical laboratory.

Faculty

Lawren VandeVrede, MD, PhD
Assistant Professor
University of California San Francisco
San Francisco, CA

Nicholas Ashton, PhD
Senior Director
Banner Sun Health Research Institute
Sun City, AZ

Disclosures and statement of independence

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.

The following faculty reported financial relationships:

• Lawren VandeVrede, MD, PhD
  • Honorarium: Peerview CME, Haymarket
  • Consulting Fees: Roche, Biogen, Siemens, Guidepoint Global Consulting
  • Grant and/or Research Support: LabCorp, Quanterix, C2N
  • Committee and/or Advisory Board: Biogen, Siemens

The following faculty reported no financial relationships:

• Nicholas Ashton, PhD

Content validity

All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.

Accreditation statement

This activity will be submitted for 1.0 ACCENT continuing education credit.

Successful completion statement

Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].